Labtec and GSK finalise licence agreement

GlaxoSmithKline obtains exclusive rights for an innovative topical patch to treat cold sores

The consumer healthcare division of GlaxoSmithKline has acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec, the transdermal and topical patch specialist based in Langenfeld, Germany. The agreement designates Labtec as the exclusive manufacturer.

The product is based on Labtec’s proprietary LabiPatch platform technology, which is especially suitable for easy, convenient application of patches on the delicate surface of the lip. Encompassing patches with and without active ingredients, the LabiPatch technology is designed to promote the healing process by maintaining a moist and optimal healing environment.

‘In GlaxoSmithKline we have found an outstanding development and marketing partner for our innovative patch technology,’ said Ingo Lehrke, managing director of Labtec. ‘We are confident that this partnership will deliver improved therapy options for a multitude of patients suffering from cold sores.’

Companies